The endometriosis market is to increase at a compound annual growth rate (CAGR) of 5.86% through to 2016, driven by the increasing number of incidence rates, and the increasing number of awareness programs.
Endometriosis is a gynecological medical condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the membrane which lines the abdominal cavity. The uterine cavity is lined with endometrial cells, which are under the influence of female hormones.
Endometrial-like cells in areas outside the uterus (endometriosis) are influenced by hormonal changes and respond in a way that is similar to the cells found inside the uterus. Symptoms often worsen with the menstrual cycle.
As per the estimates of World Endometriosis Research Foundation, an estimated 170 million women suffer from endometriosis globally. The disease represents one of the major causes of female infertility constituting for about 30% of infertility cases in women.
Present drugs mainly provide short-term relief of disease symptoms, without providing an absolute cure for endometriosis. The drugs presently available in the market are lowest on efficacy and safety profiles and may lead to adverse effects, which primarily include loss of bone density as well as several menopause-like side effects.
Lupron (Leuprolide) represents one of the leading drugs for the treatment of endometriosis. Lupron Depot from Abbott Laboratories, Depo-Provera and Synarel from Pfizer, are the major drugs approved for the treatment of endometriosis.
The emergence of certain other promising innovative drugs, including Repros Therapeutics' Proellex, Neurocrine's Elagolix, and Bayer HealthCare Pharmaceuticals' Visanne (Dienogest) is forecast to have a robust impact on the endometriosis market in future.
The future looks promising for endometriosis, with increasing efforts being made in research and novel treatment emerging in the field of surgical as well as pharmaceutical treatment. In addition, myths are being dispelled regarding the disease and alternative methods are being readily accepted.
Non-invasive diagnostics, including next-generation MRIs, are forecast to become major tools for the diagnosis of endometriosis, although laparoscopy, an invasive surgery, still remains the gold standard for performing disease diagnosis.
For more information on the endometriosis market, see the latest research: Endometriosis Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.